The ups and downs of STAT3 function: too much, too little and human immune dysregulation
Clinical and Experimental Immunology · 25.04.2023 · 212 (2) · 107-116
DOI: 10.1093/cei/uxad007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 18.01.2023. Verfasst von Joseph Mackie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Immunity. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Health and Medical Research Council, American Association of Immunologists, Job Research Foundation.
Abstract (Originalsprache)
The STAT3 story has almost 30 years of evolving history. First identified in 1994 as a pro-inflammatory transcription factor, Signal Transducer and Activator of Transcription 3 (STAT3) has continued to be revealed as a quintessential pleiotropic signalling module spanning fields including infectious diseases, autoimmunity, vaccine responses, metabolism, and malignancy. In 2007, germline heterozygous dominant-negative loss-of-function variants in STAT3 were discovered as the most common cause for a triad of eczematoid dermatitis with recurrent skin and pulmonary infections, first described in 1966. This finding established that STAT3 plays a critical non-redundant role in immunity against some pathogens, as well as in the connective tissue, dental and musculoskeletal systems. Several years later, in 2014, heterozygous activating gain of function germline STAT3 variants were found to be causal for cases of early-onset multiorgan autoimmunity, thereby underpinning the notion that STAT3 function needed to be regulated to maintain immune homeostasis. As we and others continue to interrogate biochemical and cellular perturbations due to inborn errors in STAT3, we will review our current understanding of STAT3 function, mechanisms of disease pathogenesis, and future directions in this dynamic field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
- School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Kensington, NSW, Australia.
ORCID-Profile: Stuart G Tangye
Förderung
- National Health and Medical Research Council
- American Association of Immunologists
- Job Research Foundation
Zitieren
APA
Mackie, J., Ma, C. S., Tangye, S. G., & Guerin, A. (2023). The ups and downs of STAT3 function: too much, too little and human immune dysregulation. Clinical and Experimental Immunology, 212(2), 107-116. https://doi.org/10.1093/cei/uxad007
Vancouver
Mackie J, Ma CS, Tangye SG, Guerin A. The ups and downs of STAT3 function: too much, too little and human immune dysregulation. Clinical and Experimental Immunology. 2023;212(2):107-116. doi:10.1093/cei/uxad007
BibTeX
@article{Mackie2023,
author = {Mackie, Joseph and Ma, Cindy S and Tangye, Stuart G and Guerin, Antoine},
title = {The ups and downs of STAT3 function: too much, too little and human immune dysregulation},
journal = {Clinical and Experimental Immunology},
year = {2023},
volume = {212},
number = {2},
pages = {107--116},
doi = {10.1093/cei/uxad007}
}
EUVIMED